Exchange: NASDAQ·Updated 07:59 PM EST

OVID News

News
all
press releases
Ovid Therapeutics (NASDAQ:OVID) Stock Crosses Below Fifty Day Moving Average - Here's Why
Ovid Therapeutics (NASDAQ:OVID) Stock Price Breaks Below 50 Day Moving Average - Should You Sell...
MarketBeat
Ovid Therapeutics (NASDAQ:OVID) Stock Crosses Below Fifty Day Moving Average - Here's Why
Ovid Therapeutics (NASDAQ:OVID) Stock Price Breaks Below 50 Day Moving Average - Should You Sell...
MarketBeat
More News
Ovid Therapeutics Inc. (OVID) Presents at UBS Global Biopharma Conference 2026 Prepared Remarks Transcript...
SeekingAlpha
Anika (ANIK) delivered earnings and revenue surprises of +70.59% and +3.94%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Vera Therapeutics (VERA) delivered earnings and revenue surprises of +24.42% and +291.95%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial OfficerPR NewswireNEW YORK, Oct. 15, 2026NEW YORK, Oct. 15, 2026...
PR Newswire
Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of +20.00% and +388.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Outlook Therapeutics, Inc. (OTLK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks

Advertisement|Remove ads.